Lompat ke isi

Rosuvastatin: Perbedaan antara revisi

Dari Wikipedia bahasa Indonesia, ensiklopedia bebas
Jelajahi riwayat secara interaktif
← Revisi sebelumnyaRevisi selanjutnya →
Konten dihapus Konten ditambahkan
VisualTeks wiki
WanaraLima (bicara | kontrib)
1.684 suntingan
Artikel baru tentang topik farmasi yang masih memerlukan tambahan dan pengembangan. Artikel ini merupakan terjemahan wikipedia bahasa Inggris masih perlu ditinjau ulang juga disesuaikan dengan padanan bahasa Indonesia
Mr. Ibrahem (bicara | kontrib)
49 suntingan
Fix references, Expend infobox mdwiki.toolforge.org.
Baris 3: Baris 3:
<!-- Clinical data -->|pregnancy_AU=D|pregnancy_US=X|routes_of_administration=[[Oral administration|By mouth]] ([[Tablet (pharmacy)|tablets]])|Drugs.com={{drugs.com|monograph|rosuvastatin-calcium}}|MedlinePlus=a603033|licence_EU=<!-- EMA uses INN (or special INN_EMA) -->|DailyMedID=Rosuvastatin|licence_US=<!-- FDA may use generic or brand name (generic name preferred) -->|pregnancy_category=|dependency_liability=|legal_AU=S4|legal_CA=<!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->|legal_UK=POM|legal_US=Rx-only|legal_status=Rx-only
<!-- Clinical data -->|pregnancy_AU=D|pregnancy_US=X|routes_of_administration=[[Oral administration|By mouth]] ([[Tablet (pharmacy)|tablets]])|Drugs.com={{drugs.com|monograph|rosuvastatin-calcium}}|MedlinePlus=a603033|licence_EU=<!-- EMA uses INN (or special INN_EMA) -->|DailyMedID=Rosuvastatin|licence_US=<!-- FDA may use generic or brand name (generic name preferred) -->|pregnancy_category=|dependency_liability=|legal_AU=S4|legal_CA=<!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->|legal_UK=POM|legal_US=Rx-only|legal_status=Rx-only


<!-- Pharmacokinetic data -->|bioavailability=20%<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018 />|protein_bound=88%<ref name=PK /><ref name=AHFS2018 />|metabolism=[[Liver]]: [[CYP2C9]] (major) and [[CYP2C19]]-mediated; ~10% metabolized<ref name=PK /><ref name=AHFS2018 />|elimination_half-life=19 hours<ref name=PK /><ref name=AHFS2018 />|excretion=[[Feces]] (90%)<ref name=PK /><ref name=AHFS2018 />
<!-- Pharmacokinetic data -->|bioavailability=20%<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018>{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>|protein_bound=88%<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018>{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>|metabolism=[[Liver]]: [[CYP2C9]] (major) and [[CYP2C19]]-mediated; ~10% metabolized<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018>{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>|elimination_half-life=19 hours<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018>{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>|excretion=[[Feces]] (90%)<ref name=PK>{{cite journal|last=Aggarwal|first=RK|author2=Showkathali, R|title=Rosuvastatin calcium in acute coronary syndromes|journal=Expert Opinion on Pharmacotherapy|date=June 2013|volume=14|issue=9|pages=1215–1227|doi=10.1517/14656566.2013.789860|pmid=23574635|url=https://semanticscholar.org/paper/a568d46e234e3510d8819d45122a2e8108896ca0|access-date=29 November 2019|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829041855/https://www.semanticscholar.org/paper/Rosuvastatin-calcium-in-acute-coronary-syndromes-Aggarwal-Showkathali/a568d46e234e3510d8819d45122a2e8108896ca0|url-status=live}}</ref><ref name=AHFS2018>{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>


<!-- Chemical and physical data -->|chemical_formula=|C=22|H=28|F=1|N=3|O=6|S=1|molecular_weight=481.539|smiles=OC(=O)C[C@H](O)C[C@H](O)\C=C\c1c(C(C)C)nc(N(C)S(=O)(=O)C)nc1c2ccc(F)cc2|StdInChI_Ref={{stdinchicite|changed|chemspider}}|StdInChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1|StdInChI_comment=|StdInChIKey_Ref={{stdinchicite|changed|chemspider}}|StdInChIKey=BPRHUIZQVSMCRT-VEUZHWNKSA-N|density=|melting_point=|melting_high=|melting_notes=|boiling_point=|boiling_notes=|solubility=|specific_rotation=}}
<!-- Chemical and physical data -->|chemical_formula=|C=22|H=28|F=1|N=3|O=6|S=1|molecular_weight=481.539|smiles=OC(=O)C[C@H](O)C[C@H](O)\C=C\c1c(C(C)C)nc(N(C)S(=O)(=O)C)nc1c2ccc(F)cc2|StdInChI_Ref={{stdinchicite|changed|chemspider}}|StdInChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1|StdInChI_comment=|StdInChIKey_Ref={{stdinchicite|changed|chemspider}}|StdInChIKey=BPRHUIZQVSMCRT-VEUZHWNKSA-N|density=|melting_point=|melting_high=|melting_notes=|boiling_point=|boiling_notes=|solubility=|specific_rotation=}}


'''Rosuvastatin''', adalah obat golongan [[statin]], digunakan untuk mencegah [[penyakit kardiovaskular]] pada individu yang memiliki risiko tinggi dan mengatasi [[Dislipidemia|lipid abnormal]] . <ref name="AHFS2018">{{Cite web|title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live |access-date=24 December 2018}}</ref> Pada penggunaan obat ini direkomendasikan bersama dengan perubahan pola makan, berolahraga, dan menurunkan berat badan. <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref> Penggunaan obat ini diberikan secara oral. <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>
'''Rosuvastatin''', adalah obat golongan [[statin]], digunakan untuk mencegah [[penyakit kardiovaskular]] pada individu yang memiliki risiko tinggi dan mengatasi [[Dislipidemia|lipid abnormal]] . <ref name=AHFS2018>{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref> Pada penggunaan obat ini direkomendasikan bersama dengan perubahan pola makan, berolahraga, dan menurunkan berat badan. <ref name=AHFS2018 /> Penggunaan obat ini diberikan secara oral. <ref name=AHFS2018 />


Kejadian efek samping obat yang umum terjadi seperti sakit perut, mual, sakit kepala, dan [[Mialgia|nyeri otot]] . <ref name="AHFS2018">{{Cite web|title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live |access-date=24 December 2018}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/rosuvastatin-calcium.html "Rosuvastatin Calcium Monograph for Professionals"]. ''Drugs.com''. [[American Society of Health-System Pharmacists]] (AHFS). [https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html Archived] from the original on 24 December 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">24 December</span> 2018</span>.</cite></ref> Efek samping yang serius pada penggunaan obat ini yakni [[Rabdomiolisis|rhabdomyolysis]], gangguan hepar, dan [[Diabetes melitus|diabetes]] . <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref> Obat ini tidak direkomendasikan pada ibu hamil karena, membahayakan janin. <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref> Seperti golongan statin lainnya, rosuvastatin mekanisme kerjanya dengan menghambat HMG-CoA reduktase, [[enzim]] yang terdapat di [[hati]] yang berperan dalam memproduksi [[kolesterol]] . <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>
Kejadian efek samping obat yang umum terjadi seperti sakit perut, mual, sakit kepala, dan [[Mialgia|nyeri otot]] . <ref name=AHFS2018 /> Efek samping yang serius pada penggunaan obat ini yakni [[Rabdomiolisis|rhabdomyolysis]], gangguan hepar, dan [[Diabetes melitus|diabetes]] . <ref name=AHFS2018 /> Obat ini tidak direkomendasikan pada ibu hamil karena, membahayakan janin. <ref name=AHFS2018 /> Seperti golongan statin lainnya, rosuvastatin mekanisme kerjanya dengan menghambat HMG-CoA reduktase, [[enzim]] yang terdapat di [[hati]] yang berperan dalam memproduksi [[kolesterol]] . <ref name=AHFS2018 />


Obat rosuvastatin pertama kali dipatenkan pada tahun 1991, dan disetujui untuk medis di Amerika Serikat pada tahun 2003. <ref name="AHFS2018">{{Cite web|title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live |access-date=24 December 2018}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/rosuvastatin-calcium.html "Rosuvastatin Calcium Monograph for Professionals"]. ''Drugs.com''. [[American Society of Health-System Pharmacists]] (AHFS). [https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html Archived] from the original on 24 December 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">24 December</span> 2018</span>.</cite></ref> <ref name="Fis2006">{{Cite book|last=Fischer|first=Janos|last2=Ganellin|first2=C. Robin|date=2006|url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA473|title=Analogue-based Drug Discovery|publisher=John Wiley & Sons|isbn=9783527607495|page=473|access-date=24 December 2018|archive-url=https://web.archive.org/web/20181224220126/https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA473|archive-date=24 December 2018|url-status=live}}</ref> Obat ini juga tersedia dalam [[obat generik]] . <ref name="AHFS2018">{{cite web |title=Rosuvastatin Calcium Monograph for Professionals |url=https://www.drugs.com/monograph/rosuvastatin-calcium.html |website=Drugs.com |publisher=[[American Society of Health-System Pharmacists]] (AHFS) |accessdate=24 December 2018 |archive-date=24 December 2018 |archive-url=https://web.archive.org/web/20181224170456/https://www.drugs.com/monograph/rosuvastatin-calcium.html |url-status=live }}</ref>
Obat rosuvastatin pertama kali dipatenkan pada tahun 1991, dan disetujui untuk medis di Amerika Serikat pada tahun 2003. <ref name=AHFS2018 /> <ref name="Fis2006">{{Cite book|last=Fischer|first=Janos|last2=Ganellin|first2=C. Robin|date=2006|url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA473|title=Analogue-based Drug Discovery|publisher=John Wiley & Sons|isbn=9783527607495|page=473|access-date=24 December 2018|archive-url=https://web.archive.org/web/20181224220126/https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA473|archive-date=24 December 2018|url-status=live}}</ref> Obat ini juga tersedia dalam [[obat generik]] . <ref name=AHFS2018 />


== Referensi ==
== Referensi ==

Revisi per 10 Februari 2024 14.10

Nama sistematis (IUPAC)
(3R,5S,6E)-7-[4-(4-Fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
Data klinis
Nama dagang Crestor, Rosulip, Zuvamor, others
AHFS/Drugs.com monograph
MedlinePlus a603033
Data lisensi US Daily Med:pranala
Kat. kehamilan D(AU) X(US)
Status hukum Harus dengan resep dokter (S4) (AU) POM (UK) ℞-only (US) ℞ Preskripsi saja
Rute By mouth (tablets)
Data farmakokinetik
Bioavailabilitas 20%[1][2]
Ikatan protein 88%[1][2]
Metabolisme Liver: CYP2C9 (major) and CYP2C19-mediated; ~10% metabolized[1][2]
Waktu paruh 19 hours[1][2]
Ekskresi Feces (90%)[1][2]
Pengenal
Kode ATC ?
Data kimia
Rumus C22H28FN3O6S 
Massa mol. 481.539
SMILES eMolecules & PubChem

  • InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1 N
    Key:BPRHUIZQVSMCRT-VEUZHWNKSA-N N

Rosuvastatin, adalah obat golongan statin, digunakan untuk mencegah penyakit kardiovaskular pada individu yang memiliki risiko tinggi dan mengatasi lipid abnormal . [2] Pada penggunaan obat ini direkomendasikan bersama dengan perubahan pola makan, berolahraga, dan menurunkan berat badan. [2] Penggunaan obat ini diberikan secara oral. [2]

Kejadian efek samping obat yang umum terjadi seperti sakit perut, mual, sakit kepala, dan nyeri otot . [2] Efek samping yang serius pada penggunaan obat ini yakni rhabdomyolysis, gangguan hepar, dan diabetes . [2] Obat ini tidak direkomendasikan pada ibu hamil karena, membahayakan janin. [2] Seperti golongan statin lainnya, rosuvastatin mekanisme kerjanya dengan menghambat HMG-CoA reduktase, enzim yang terdapat di hati yang berperan dalam memproduksi kolesterol . [2]

Obat rosuvastatin pertama kali dipatenkan pada tahun 1991, dan disetujui untuk medis di Amerika Serikat pada tahun 2003. [2] [3] Obat ini juga tersedia dalam obat generik . [2]

Referensi

  1. ^ a b c d e Aggarwal, RK; Showkathali, R (June 2013). "Rosuvastatin calcium in acute coronary syndromes". Expert Opinion on Pharmacotherapy. 14 (9): 1215–1227. doi:10.1517/14656566.2013.789860. PMID 23574635. Diarsipkan dari versi asli tanggal 29 August 2021. Diakses tanggal 29 November 2019. 
  2. ^ a b c d e f g h i j k l m n "Rosuvastatin Calcium Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists (AHFS). Diarsipkan dari versi asli tanggal 24 December 2018. Diakses tanggal 24 December 2018. 
  3. ^ Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. hlm. 473. ISBN 9783527607495. Diarsipkan dari versi asli tanggal 24 December 2018. Diakses tanggal 24 December 2018. 
Ikon rintisan

Artikel bertopik farmasi ini adalah sebuah rintisan. Anda dapat membantu Wikipedia dengan mengembangkannya.

Diperoleh dari "https://wiki-indonesia.club/w/index.php?title=Rosuvastatin&oldid=25293597"